Talking the talk on walking the walk - A 12-item generic walking scale suitable for neurological conditions?
Talking the talk on walking the walk - A 12-item generic walking scale suitable for neurological conditions?
复制标题
DOI：
10.1007/s00415-006-0272-2
复制
发表时间：
2006-12-01
影响因子：
6
通讯作者：
Hobart, J. C.
中科院分区：
文献类型：
--
作者：
Holland, A.;O'Connor, R. J.;Hobart, J. C.
背景 多发性硬化症步行量表 (MSWS-12) 是为了测量多发性硬化症对步行的影响而开发的。许多其他致残性神经系统疾病会影响患者的行走能力，步行的通用测量可以为临床试验、流行病学研究以及常规临床实践中患者的感知提供有价值的见解。目的 评估步行影响量表 (Walk-12)（MSWS-12 的修改版）在神经系统疾病患者中的临床实用性和心理测量特性。设计 对 120 名连续入院康复的患者进行前瞻性观察研究。 Walk-12 用于测量神经功能障碍对步行的影响。 Traditional psychometric methods (data quality, scaling assumptions, targeting, reliability, validity and responsiveness) were used to assess the Walk-12.出院时使用过渡问题来衡量对变化的感知。还使用定时步行测试 (TWT)、巴塞尔指数 (BI) 和功能独立测量 (FIM) 来测量结果。结果整个组的缺失数据很少，满足尺度假设，内部一致性为0.94。 Walk-12 与 TWT、BI 和 FIM 运动评分之间的相关性中等（r = -0.58、-0.26、-0.31）。 Walk-12 的响应度很高（效应大小 = 1.12）。效应大小与患者和物理治疗师对步行变化的看法之间的关系表现出良好的一致性。初步亚组分析表明不同神经系统疾病的心理测量特性令人满意；然而，这些分析中的样本数量很少。结论 在神经功能障碍患者样本中，Walk-12 在临床上有用并且满足标准心理测量标准。这提供了初步证据，表明它可能适合作为步行能力的通用衡量标准。
Background The Multiple Sclerosis Walking Scale (MSWS-12) was developed to measure the impact of multiple sclerosis on walking. Many other disabling neurological conditions affect patients' ability to walk, and a generic measure of walking could provide valuable insights into patients' perceptions in clinical trials and epidemiological studies as well as routine clinical practice. Objective To evaluate the clinical usefulness and psychometric properties of the Walking Impact Scale (Walk-12), a modified version of the MSWS-12, in patients with neurological conditions. Design A prospective, observational study of 120 consecutive patients admitted for rehabilitation. The Walk-12 was used to measure the impact of neurological disability on walking. Traditional psychometric methods (data quality, scaling assumptions, targeting, reliability, validity and responsiveness) were used to assess the Walk-12. Transition questions were used on discharge to measure perception of change. Outcome was also measured using the timed walk test (TWT), Barthel Index (BI) and Functional Independence Measure (FIM). Results For the total group, missing data were few, scaling assumptions were satisfied, and internal consistency was 0.94. Correlations between the Walk-12 and TWT, BI and FIM motor score were moderate (r = -0.58, -0.26, -0.31). Responsiveness of the Walk-12 was high (effect size = 1.12). Relationships between effect size and patients' and physiotherapists' opinion of change in walking demonstrated good concordance. Preliminary subgroup analyses indicate satisfactory psychometric properties across different neurological conditions; however, sample numbers in these analyses are small. Conclusions In this sample of neurologically disabled patients the Walk-12 was clinically useful and satisfied standard psychometric criteria. This provides preliminary evidence that it may be suitable as a generic measure of walking ability.